Datapoint: Alvotech and Teva Plot Broader Simlandi Launch

Alvotech and Teva Pharmaceutical Industries Ltd. Signed a “long-term agreement” to bring its Simlandi (adalimumab) biosimilar to market with an undisclosed partner, according to press reports. In February, the FDA designated Simlandi as the first biosimilar to be interchangeable with Humira (adalimumab), the best-selling drug from AbbVie that treats a variety of autoimmune conditions. With an interchangeable status, a biosimilar can be substituted for a reference biologic by a pharmacist with a provider’s approval. Simlandi had previously struggled to gain FDA approval, making it a late entrant in the burgeoning Humira biosimilar field. Humira continues to hold covered or better status for 91% of all insured lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 4/26/24

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: Cigna, Oscar to End Small Group Partnership

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 15

Datapoint: FDA Approves Pfizer’s Hemophilia B Treatment

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 14

Datapoint: Sandoz Reaches Agreement With Amgen to Launch Prolia, Xgeva Biosimilars

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today